Back to top
more

Beam Therapeutics (BEAM)

(Delayed Data from NSDQ)

$31.03 USD

31.03
1,883,819

+2.70 (9.53%)

Updated Aug 25, 2026 04:00 PM ET

After-Market: $31.02 -0.01 (-0.03%) 5:54 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 35% (159 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

The Zacks Analyst Blog Highlights: CRISPR Therapeutics, Editas Medicine, Sarepta Therapeutics and Beam Therapeutics

by Zacks Equity Research

The Zacks Analyst Blog Highlights: CRISPR Therapeutics, Editas Medicine, Sarepta Therapeutics and Beam Therapeutics

Indrajit Bandyopadhyay headshot

4 Biotechs to Watch Amid Rising Prominence of Gene Therapies

by Indrajit Bandyopadhyay

Here we discuss four biotech companies, CRSP, EDIT, SRPT and BEAM, that have the potential to gain from their promising gene therapy pipeline candidates.

Zacks Equity Research

Editas (EDIT) Focuses on Developing Gene Drug for Eye Disease

by Zacks Equity Research

Editas (EDIT) progresses well with the development of its lead candidate, EDIT-101, to treat LCA10, a rare genetic illness that causes blindness. Dependence on partners for revenues is a concern.

Zacks Equity Research

Editas (EDIT) Down on Initial Data From Eye Disease Study

by Zacks Equity Research

Editas (EDIT) posts initial data from the phase I/II BRILLIANCE study evaluating EDIT-101 for treating Leber congenital amaurosis 10, an inherited form of blindness.

Zacks Equity Research

Editas (EDIT) Up More Than 70% in Past 3 Months: Here's Why

by Zacks Equity Research

Editas' (EDIT) lead candidate, EDIT-101, which employs CRISPR gene editing to treat LCA10, holds potential. The company is also developing EDIT-301 for treating hematologic diseases.

Sweta Jaiswal, FRM headshot

How Are Genomics ETFs Responding to Q2 Earnings?

by Sweta Jaiswal, FRM

Let's take a look at some big genomics earnings releases to see if these will impact ETFs exposed to the space.

Zacks Equity Research

Company News for Aug 11, 2021

by Zacks Equity Research

Companies In The News Are: VSH, SYY, NOVT, BEAM

Zacks Equity Research

Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Beam Therapeutics Inc. (BEAM) delivered earnings and revenue surprises of -63.79% and -99.98%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Beam Therapeutics Inc. (BEAM) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

by Zacks Equity Research

Beam Therapeutics Inc. (BEAM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sweta Jaiswal, FRM headshot

A Comprehensive Guide to Genomic ETFs

by Sweta Jaiswal, FRM

Genomic ETFs are expected to benefit from the favorable trends in the genomic editing space.